REVIEW OF ECONOMIC EVIDENCE ON THE IMPACT OF SUBSTANDARD AND FALSIFIED MEDICINES IN LOW AND MIDDLE INCOME COUNTRIES
Author(s)
Ozawa S, Bessias S, Haynie D, Yemeke T, Herrington J
University of North Carolina at Chapel Hill, Chapel hill, NC, USA
Presentation Documents
OBJECTIVES: To examine the extent of substandard and falsified essential medicines in low and middle income countries (LMIC) and assess evidence of their economic impact. METHODS: Five databases were searched for articles containing data on prevalence and/or economic impact of substandard and falsified medicines in LMICs: PubMed, EconLit, Global Health, EMBASE, and SCOPUS. The search used variations of two keywords: “substandard and falsified medicines” and “low- and middle-income country.” Studies that did not seek to quantify either prevalence or economic impact of substandard and falsified essential medicines, or that pertained only to high income countries were excluded. Additional gray literature sources were incorporated through reference mining. Two reviewers independently assessed articles for inclusion. Data describing the setting, medicine, disease target, prevalence, and economic impact were extracted from selected articles. RESULTS: Our initial search yielded 1,783 unique records. We identified 106 studies that estimated the prevalence of substandard and falsified essential medicines in LMICs with primary data collection. Results from country studies suggest considerable variation in the prevalence of the problem across regions, specific medicines and facilities (hospitals vs. pharmacies), as well as in the source of the evidence (active vs. passive surveillance). We found no primary data characterizing the economic impact of substandard and falsified medicines. However, we identified 68 studies that cited an estimate of economic impact from other non-primary sources. CONCLUSIONS: This review demonstrates that substandard and falsified medicines are a substantial and understudied problem in LMICs. More prevalence data on poor quality medicines are needed for precision and generalizability. It further highlights key gaps in the available literature at estimating the economic impact of substandard and falsified medicines. Further studies are needed to evaluate the broader economic impact of poor quality medicines in LMICs and to make a case for investing in evidence-based solutions to address this problem.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PHP32
Topic
Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity, Pricing Policy & Schemes
Disease
Multiple Diseases